Ovid Therapeutics Inc.

NasdaqGS:OVID Stok Raporu

Piyasa değeri: US$83.7m

Ovid Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Ovid Therapeutics'in kazancının yıllık 21.4% oranında azalması, yıllık gelirinin ise yıllık 49.2% oranında artması beklenmektedir. EPS'nin düşmesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -170.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

-21.4%

Kazanç büyüme oranı

-14.9%

EPS büyüme oranı

Biotechs kazanç büyümesi27.3%
Gelir büyüme oranı49.2%
Gelecekteki özkaynak getirisi-170.9%
Analist kapsamı

Good

Son güncelleme14 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13
Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09
We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16
Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20
Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18
Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01
We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25
Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21
Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:OVID - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202622-34N/AN/A4
12/31/20255-55N/AN/A6
12/31/20240-35N/AN/A8
6/30/20241-30-53-53N/A
3/31/20240-51-50-50N/A
12/31/20230-52-46-46N/A
9/30/20230-49-43-43N/A
6/30/20230-49-46-46N/A
3/31/20230-51-49-47N/A
12/31/20222-54-57-55N/A
9/30/20221-68-60-58N/A
6/30/20221-66-58-56N/A
3/31/20221-67-63-62N/A
12/31/2021208120118119N/A
9/30/2021214123116116N/A
6/30/2021221117125126N/A
3/31/2021221110128128N/A
12/31/202013-81-52-52N/A
9/30/20207-76-54-54N/A
6/30/2020N/A-76-62-62N/A
3/31/2020N/A-67-57-57N/A
12/31/2019N/A-60-51-51N/A
9/30/2019N/A-56-45-45N/A
6/30/2019N/A-53-46-46N/A
3/31/2019N/A-53-46-45N/A
12/31/2018N/A-52-46-46N/A
9/30/2018N/A-50-44-44N/A
6/30/2018N/A-46-43-43N/A
3/31/2018N/A-44N/A-37N/A
12/31/2017N/A-65N/A-31N/A
9/30/2017N/A-61N/A-28N/A
6/30/2017N/A-58N/A-23N/A
3/31/2017N/A-53N/A-21N/A
12/31/2016N/A-22N/A-18N/A
9/30/2016N/A-18N/A-14N/A
12/31/2015N/A-13N/A-5N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OVID önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: OVID önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: OVID önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: OVID şirketinin gelirinin (yıllık 49.2% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OVID şirketinin gelirinin (yıllık 49.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OVID 3 yıl içinde kârsız olması bekleniyor.


Büyüyen şirketleri keşfedin